Trade War‘s Next Frontier? China Genetic Material Regs Could Set Back Biopharma Research
Executive Summary
A new rule regulating the collecting, storing and transporting of genetic samples and materials in China sets new limits on international companies looking to conduct work with biologic and gene therapies in potentially the most promising market for these emerging technologies.
You may also be interested in...
Gene And Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?
The first country ever to approve a gene therapy, China has subsequently lagged in the area due to a lack of clear regulatory pathways and insufficient financial incentives. Now a new crop of developers are aiming to revitalize ambitions and make the country a major power for promising novel treatments for rare neurodegenerative conditions, retinal dystrophy, HIV and cancer.
Chinese Scientist Behind Gene Edited Babies Gets 3 Year Jail Term
Scientific experiment now a criminal charge and the scientist He Jiankui is sentenced to three years in prison and also levied a fine.Two collaborators face similar fate.
Gene And Cell Therapies In Asia: Can China Deliver Despite Murky Regulations?
The first country ever to approve a gene therapy, China has been lagging in the area since due to a lack of clear regulatory pathways and insufficient financial incentives. Now a new crop of developers are aiming to revitalize ambitions and make the country a major power for promising novel treatments for rare neurodegenerative conditions, retinal dystrophy, HIV and cancer.